Clinical Trials
35 trialsNCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT07124000 2026-05-01
DP-04
AstraZeneca
Recruiting
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT06187103 2026-04-21
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
Active not recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT07318051 2026-01-15
SCORE
Natera, Inc.
Recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT06970275 2025-12-05
PETRiS
XEOS Medical
Recruiting
NCT05812027 2025-11-17
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
Active not recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06385587 2025-10-20
SYMTECH01
Aptar Digital Health
Completed
NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
NCT05406167 2025-08-15
PREMIER
RefleXion Medical
Recruiting
NCT04825834 2025-08-08
DELFI-L101
Delfi Diagnostics Inc.
Completed
NCT04050761 2025-07-02
ProNiHN
Bristol-Myers Squibb
Completed
NCT03114163 2025-06-18
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Bristol-Myers Squibb
Completed
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04510129 2025-03-12
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
Recruiting
NCT05697198 2025-03-06
PREFER
Labcorp Corporation of America Holdings, Inc
Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06618170 2024-10-02
ETCETERA
Dyameo
Not yet recruiting
NCT03157674 2024-01-05
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Bristol-Myers Squibb
Completed
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT05801770 2023-04-06
Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences
Power Life Sciences Inc.
Unknown
NCT05061940 2022-12-06
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Repertoire Immune Medicines
Terminated
NCT04545632 2022-07-27
DETECT
Boryung Pharmaceutical Co., Ltd
Completed
NCT03569436 2022-02-10
Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
Bristol-Myers Squibb
Completed
NCT05049408 2021-09-28
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
S&T Biomed Co., Ltd.
Completed
NCT04697446 2021-08-10
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Blueprint Medicines Corporation
Unknown
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT04066335 2019-12-18
Study to Evaluate the Safety of Nanoxel M Inj.
Samyang Biopharmaceuticals Corporation
Unknown
NCT02705833 2017-04-24
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
Bristol-Myers Squibb
Completed
NCT01075828 2014-08-29
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Merck KGaA, Darmstadt, Germany
Completed
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT01080313 2012-02-13
LORHAN
Eli Lilly and Company
Completed